Hansoh Pharmaceutical (03692.HK): NMPA Accepts New Drug Application for Orlotide Injection
NewTimeSpace News: On June 4, 2026, Hansoh Pharmaceutical (03692.HK) issued a voluntary announcement, disclosing that on June 3, 2026, the marketing authorization application for its in-house innovative product Orlotide Injection was accepted by the National Medical Products Administration (NMPA). The indication covers long-term weight management for adult patients with obesity or overweight.
Orlotide is a once-weekly dual agonist targeting GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Hansoh Pharmaceutical (03692.HK): Enters Licensing and Equity Investment Transaction with Avere Therapeutics
- HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA
- HANSOH PHARMA(03692.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.26 billion, YoY increase of 35.82%
- HANSOH PHARMA (03692.HK): Self-Developed Class 1 New Drug HS-10582 Tablet Receives NMPA Clinical Trial Approval Notice for Primary Hypercholesterolemia
- Hansoh Pharmaceutical (03692.HK): HS-20093 Meets Primary Endpoint in Phase III Osteosarcoma Trial, to Advance NDA Filing
